흑색종 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 치료법별, 질환 유형별, 용도별, 지역별, 경쟁별 세분화(2020-2030년)

The Global Melanoma Drugs Market will grow from USD 7.42 Billion in 2024 to USD 11.98 Billion by 2030 at a 8.31% CAGR. Melanoma drugs refer to pharmaceutical agents developed to treat melanoma, an aggressive form of skin cancer, by targeting and inhibiting the proliferation and spread of malignant cells. The market's growth is predominantly driven by the increasing global incidence of melanoma and advancements in diagnostic technologies enabling earlier disease detection.

Key Market Drivers

The increasing incidence of melanoma globally represents a fundamental driver for the melanoma drugs market. The rise in diagnoses directly expands the patient pool requiring therapeutic intervention, thereby escalating demand for effective treatments. According to the American Cancer Society, in February 2025, an estimated 104,960 new cases of invasive melanoma are expected to be diagnosed in the United States this year. This growing patient demographic underscores the urgent need for a continuous supply of both existing and novel pharmaceutical solutions. Factors such as increased ultraviolet radiation exposure and improved diagnostic capabilities contribute to these rising numbers, highlighting a persistent and evolving challenge in public health that fuels market expansion.

Key Market Challenges

The substantial cost associated with innovative melanoma treatments represents a significant impediment to the growth of the global melanoma drugs market. The high pricing of novel targeted therapies and immunotherapies directly impacts patient access and the overall sustainability of healthcare systems. This financial burden, often termed financial toxicity, can lead to reduced treatment initiation and adherence, even for life-extending medications.

Key Market Trends

A significant trend in the global melanoma drugs market is the shift towards multi-modal and combination therapies, which are demonstrating enhanced efficacy and improved patient outcomes. This approach involves combining different therapeutic modalities, such as immunotherapies with targeted agents, to attack cancer cells through multiple mechanisms simultaneously, thereby overcoming resistance and extending survival.

Key Market Players

• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Amgen Inc.
• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• Merck & Co. Inc
• Abbott Laboratories Inc.
• Bayer AG
• Aptose Biosciences Inc.

Report Scope:

In this report, the Global Melanoma Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Melanoma Drugs Market, By Therapy:

• Chemotherapy
• Immunotherapy
• Targeted Therapy

Melanoma Drugs Market, By Disease Type:

• Superficial Spreading Melanoma
• Lentigo Maligna
• Acral Lentiginous Melanoma
• Nodular Melanoma

Melanoma Drugs Market, By Application:

• Hospitals
• Outpatient Oncologist Clinics
• Others

Melanoma Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Melanoma Drugs Market.

Available Customizations:

Global Melanoma Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Melanoma Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy)
  • 5.2.2. By Disease Type (Superficial Spreading Melanoma, Lentigo Maligna, Acral Lentiginous Melanoma, Nodular Melanoma)
  • 5.2.3. By Application (Hospitals, Outpatient Oncologist Clinics, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Melanoma Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Disease Type
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Melanoma Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Melanoma Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Melanoma Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Application

7. Europe Melanoma Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Disease Type
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Melanoma Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Application
  • 7.3.2. France Melanoma Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Melanoma Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Melanoma Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Melanoma Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Application

8. Asia Pacific Melanoma Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Disease Type
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Melanoma Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Application
  • 8.3.2. India Melanoma Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Melanoma Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Melanoma Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Melanoma Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Application

9. Middle East & Africa Melanoma Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Disease Type
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Melanoma Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Melanoma Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Melanoma Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Application

10. South America Melanoma Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy
  • 10.2.2. By Disease Type
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Melanoma Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Melanoma Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Melanoma Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Melanoma Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bristol-Myers Squibb Company
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AstraZeneca PLC
• 15.3. Amgen Inc.
• 15.4. GlaxoSmithKline plc
• 15.5. F. Hoffmann-La Roche Ltd
• 15.6. Johnson & Johnson
• 15.7. Merck & Co. Inc
• 15.8. Abbott Laboratories Inc.
• 15.9. Bayer AG
• 15.10. Aptose Biosciences Inc.

16. Strategic Recommendations

17. About Us & Disclaimer